Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Prescription, Nonprescription and Orphan Drugs

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.

The AAPS journal·2019

Same author

How the FDA Ensures High-Quality Generic Drugs.

American family physician·2018

Same author

Drug Information Association Pharmacovigilance and Risk Management Strategies 2017: Overview of the Generic Drug Program and Surveillance.

Therapeutic innovation & regulatory science·2018

Same author

Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival.

Diabetes, obesity & metabolism·2017

Same author

Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.

Molecular pharmaceutics·2017

Same author

In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.

The AAPS journal·2017

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Generic drugs--safe, effective, and affordable.

John R Peters¹, Dena R Hixon, Dale P Conner

¹Office of Generic Drugs, U.S. Food and Drug Administration, Rockville, Maryland 20855, USA.

Dermatologic Therapy

|May 21, 2009

Summary

This article reviews the US process for generic drug approval, focusing on dermatologic products. It details in vivo bioequivalence (BE) testing and statistical criteria, using a topical antifungal as an example.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Cost-Efficient Transcriptomic-Based Drug Screening

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 23, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Cost-Efficient Transcriptomic-Based Drug Screening

Cost-Efficient Transcriptomic-Based Drug Screening

Published on: February 23, 2024

Area of Science:

Pharmacology
Dermatology
Regulatory Science

Background:

Generic drug evaluation and approval processes in the US have evolved significantly.
Locally acting dermatologic products present unique challenges in regulatory assessment.
Understanding bioequivalence is crucial for ensuring therapeutic equivalence of generic drugs.

Purpose of the Study:

To discuss the historical evolution of generic drug evaluation and approval in the United States.
To emphasize the specific requirements for locally acting dermatologic products.
To explain the in vivo bioequivalence testing and statistical criteria for these products.

Main Methods:

Review of historical regulatory documents and guidelines.
Analysis of in vivo bioequivalence (BE) testing methodologies.
Case study application using a topical antifungal dermatologic product.

Main Results:

The article outlines the established criteria for determining bioequivalence in locally acting dermatologic drugs.
An example demonstrates the practical application of BE determination for topical antifungal products.
The discussion highlights factors beyond FDA regulatory authority in prescription medication dispensing.

Conclusions:

The US generic drug approval process, particularly for dermatologic products, relies on rigorous bioequivalence testing.
Statistical criteria for bioequivalence are essential for ensuring the safety and efficacy of generic topical medications.
Regulatory frameworks continue to adapt to the complexities of drug evaluation.